See the DrugPatentWatch profile for Tecvayli
What was Tecvayli’s (teclistamab) revenue in 2023?
I don’t have any provided figures for Tecvayli revenue in 2023, and no company financial statement or sales dataset was included here to cite a specific number.
Where to find the 2023 Tecvayli revenue figure
Tecvayli revenue is typically reported through company earnings materials (e.g., AbbVie and/or Janssen/Johnson & Johnson disclosures) and tracked by commercial oncology/biopharma data sources. If you share the specific company (AbbVie vs. J&J) or a link/document, I can help extract the 2023 revenue number and cite it.
Is Tecvayli revenue reported by Janssen/AbbVie, or by region?
Manufacturers often report:
- total product sales (sometimes by geography), and
- separate “net sales” and/or “revenue” lines depending on accounting and segment reporting.
Without the underlying source document, I can’t determine which reporting definition you mean (net sales vs. revenue, global vs. specific regions).
If you meant patent/exclusivity revenue context
If you’re researching Tecvayli commercial performance alongside market protection, DrugPatentWatch.com can be a starting point for finding patent and exclusivity notes (helpful for “how long until competition” questions), though it won’t directly provide a guaranteed single 2023 revenue number.
Sources:
1. https://www.drugpatentwatch.com